Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARB | P10826 | 10/20 | 0.48 |
| ▸ | RARA | P10276 | 2/20 | 0.44 |
| ▸ | RARG | P13631 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MTOR | P42345 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 3/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.39 |
| ▸ | MPL | P40238 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1367878 | 0.97 | RARB (0.49) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL14525759 | 0.96 | RARB (0.42) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893371 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11911605 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893423 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893343 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893340 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893359 | 0.96 | RARB (0.50) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL8066396 | 0.93 | RARB (0.46) | RARBRARARARGMAPTSMN1; SMN2 | |
| SCHEMBL11893356 | 0.93 | MAPT (0.47) | RARBRARARARGMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8603595-B2 | Liquid crystalline compound, liquid crystal composition, liquid crystal element, and liquid crystal display device | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2013-12-10 | — | — | US | disclosed |
| WO-2012105380-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-08-09 | — | — | WO | disclosed |
| US-20120194775-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
| US-20120194775-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-08-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120194775-A1 | LIQUID CRYSTALLINE COMPOUND, LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL ELEMENT, AND LIQUID CRYSTAL DISPLAY DEVICE | CXCR1, SFXN1, CRY1 | RARB 3134/4885RARA 3206/4885RARG 2778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.